Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
Adenoma, Pleomorphic
/ immunology
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ metabolism
Biomarkers, Tumor
/ metabolism
CD4 Antigens
/ metabolism
CD8 Antigens
/ metabolism
Disease-Free Survival
Female
Humans
Immunity
Kaplan-Meier Estimate
Lung Neoplasms
/ immunology
Male
Middle Aged
Multivariate Analysis
Prognosis
CD4
CD8
PD-L1
Pulmonary pleomorphic carcinoma
prognosis
tumor immunity
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
14
11
2019
revised:
24
11
2019
accepted:
28
11
2019
entrez:
2
1
2020
pubmed:
2
1
2020
medline:
11
1
2020
Statut:
ppublish
Résumé
Pulmonary pleomorphic carcinoma (PPC) is a rare aggressive neoplasm, with dismal prognosis. Whether tumor immunity is associated with the progressive biological behavior of PPC remains unclear. The purpose of this study was to examine the prognostic significance of tumor immunity-related markers such as programmed death-1 ligand (PD-L1) and CD4 Ninety-nine patients with surgically resected PPC were assessed by immunohistochemistry. The expression of PD-L1, CD4, and CD8 was examined in specimens of the resected tumors. PD-L1 was highly expressed in 61% (60/99) of lesions and high expression of CD4 and CD8 was identified in 42% (42/99) and 51% (51/99) of lesions, respectively. There was no relationship between the expression PD-L1 and the numbers of CD4 A low number of CD4
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary pleomorphic carcinoma (PPC) is a rare aggressive neoplasm, with dismal prognosis. Whether tumor immunity is associated with the progressive biological behavior of PPC remains unclear. The purpose of this study was to examine the prognostic significance of tumor immunity-related markers such as programmed death-1 ligand (PD-L1) and CD4
PATIENTS AND METHODS
METHODS
Ninety-nine patients with surgically resected PPC were assessed by immunohistochemistry. The expression of PD-L1, CD4, and CD8 was examined in specimens of the resected tumors.
RESULTS
RESULTS
PD-L1 was highly expressed in 61% (60/99) of lesions and high expression of CD4 and CD8 was identified in 42% (42/99) and 51% (51/99) of lesions, respectively. There was no relationship between the expression PD-L1 and the numbers of CD4
CONCLUSION
CONCLUSIONS
A low number of CD4
Identifiants
pubmed: 31892575
pii: 40/1/261
doi: 10.21873/anticanres.13948
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
CD4 Antigens
0
CD8 Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
261-269Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.